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INTRODUCTION
Cancer genomes are replete with non-selected passenger somatic mutations that provide a historical record of the mutational processes experienced by a cell lineage. Previous work has categorized mutations by their 5 0 and 3 0 nucleotide contexts and used mathematical procedures to deconvolute ''mutation signatures'' that, in some cases, have been linked to the underlying mutational processes including spontaneous cytosine deamination, deficient mismatch repair (MMR), tobacco smoking, and UV light (Alexandrov et al., 2013) . In addition, a prevalent mutation signature in some tumors consisting of clustered C > T and C > G changes in the TCW context (where W is A or T) has been linked to the activity of the APOBEC3 (A3) family of cytosine deaminases acting on single-stranded DNA during replication and at chromosome breakpoints (Burns et al., 2013; Roberts et al., 2012; Seplyarskiy et al., 2016; Taylor et al., 2013) .
We reasoned that focusing on clustered mutations might pinpoint additional specific mutation processes operating in human somatic cells. Clustered mutations are likely to be generated by the same mutagenic event, so more specifically revealing the underlying molecular processes. Here, we report a systematic analysis of the landscape of clustered mutations in >1,000 human tumor genomes, revealing nine common signatures. These include a highly prevalent mutational signature of error-prone DNA repair that is directed toward active chromatin and associated with carcinogen exposure.
RESULTS
Systematic Discovery of Clustered Mutational Processes in Cancer Genomes
Most classes of somatic mutations are enriched in late-replicating, heterochromatic regions (Schuster-Bö ckler and Lehner, 2012; Woo and Li, 2012) due to differential DNA repair (Supek and Lehner, 2015; Zheng et al., 2014) . To identify clustered single nucleotide variants (henceforth, mutations), we thus applied a randomization test that accounts for this megabase-scale variability in mutation rates. A3 mutation tracts can extend over several kilobases (Roberts et al., 2012; Taylor et al., 2013) ; however, a naive use of a 1-kb threshold causes many genomes to exhibit artifactual mutation clusters after randomization. This is particularly evident for tumors with a high mutation burden (Figure S1A) with false discoveries preferentially stemming from the mutation-rich, late-replicating regions ( Figure S1B ). Thus, controlling for mutation rate variability is important for determining clustering patterns of passenger mutations, as it is for determining the recurrence of driver mutations (Hodis et al., 2012) .
We conservatively required pairs of mutations to be at most 500 bp apart with both mutations having the same reference and mutant nucleotides and occurring on the same DNA strand. This provided a trade-off between coverage and clustering false discovery (Figures S1C and S1D) . We analyzed tumors that have at least ten clustered mutations with at least 80% true positives. This yielded a set of 1,159 tumor samples with a 4.8% pooled false discovery rate (FDR) (STAR Methods), which excluded many samples with a very high mutation burden ( Figure S1C ). The tumors under consideration contained 92,633 clustered and 6,148,742 unclustered somatic changes (R10 kb to nearest; 214,249 remain in the intermediate class).
The variant allele fractions (VAFs) in the genome sequencing data are expected to be consistent for the mutations in a cluster if they derive from a single event. This provided an independent estimate of clustering true positive rates, ranging from 84% to 90% ( Figure S2G ; STAR Methods).
Multiple Clustered Mutation Signatures Are Evident in Cancer Genomes
While the A3 signature is enriched in mutation clusters it also contributes many unclustered mutations (Chan et al., 2015; Seplyarskiy et al., 2016) . We thus made provisions to simultaneously discover signatures in the clustered and unclustered spectra, while accounting for their different abundance via subsampling the unclustered group (STAR Methods). A principal components (PC) analysis of relative frequencies of mutational spectra (normalized per tumor; STAR Methods) revealed that clustered mutations explain $3-fold more variance than unclustered mutations in the first six PCs ( Figure 1A ). Therefore, clustered changes, even though present in low quantities ( Figure  1F ), represent informative markers of somatic mutational processes that discriminate between tumor samples. This PC analysis estimates how commonly some mutational spectrum dominates the clustered mutations observed in each tumor. A3-signature mutations are among the salient trends (Figure 1B) ; however, the corresponding TCW contexts explain less than one-fourth of the variance in the six leading PCs ( Figure 1A ). Therefore, other spectra are commonly dominant among mutation clusters in tumors: clustered A > G changes in a WA context (Figure 1B, high PC1 values) and clustered C > A and A > T changes in all contexts (due to strand symmetry, R > T, where R is a purine; high PC2 values). These trends are differentially represented across cancer types (Figures 1C and S1F) , but are consistent between independent studies of the same, or similar tissues-of-origin ( Figure S1H ). Of note, placement of the A3 signatures and the WA > WG clustered signature on the opposite ends of one PC axis does not imply their mutual exclusivity in tumors in terms of absolute mutation burden, which this PC analysis does not measure.
Additional trends in the PC analysis ( Figure S1G ) suggested that further important clustered signatures exist. We therefore applied a methodology based on non-negative matrix factorization (NMF) adapted for simultaneous discovery on clustered and unclustered contexts (STAR Methods). Bootstrap reproducibility and a comparison against a randomized baseline (Figures S2A-S2C; STAR Methods) suggested nine mutational signatures (Figure 1E) . This is likely conservative, since extracting additional signatures would capture known non-clustered mutational processes corresponding to CpG deamination and to UV damage . Seven of the nine signatures have higher NMF weights on the prominent clustered contexts than on unclustered ones ( Figure 1D ) and the unclustered weights also tend to be more uniformly distributed among 5 0 and 3 0 contexts ( Figure S2F ). This suggests that the clustered signatures provide more discriminative markers of the underlying mutagenic processes.
Types of APOBEC3 Mutagenesis Vary across Tissues
Of the nine signatures, three (signature C1-C3) correspond to the known A3 mutational contexts: TCW > TGW or TTW. Correlation with gene expression in tumors (Figure 2A ) and the broader 5 0 context of the mutations ( Figure 2B ) suggest that signatures C1 and C2 likely reflect the activity of the APOBEC3B (A3B) enzyme, a ubiquitous source of mutations in cancer (Burns et al., 2013) . In contrast, signature C3, which additionally encompasses many unclustered mutations ( Figure S2H ), more likely reflects the activity of APOBEC3A (A3A), recently also proposed to be an important mutagen (Chan et al., 2015) . Interestingly, signatures C1 and C2 exhibit a striking difference in their inter-mutation distances. An explanation for this could be a difference in the downstream pathway that repairs the uracil lesion with a processive mechanism that generates C > T and a less processive mechanism underlying C > G changes (Figure 2C) . This suggests that both the identity of the lesion-generating A3 enzyme (C1/C2 versus C3) and the mechanism of lesion processing (C1 versus C2) varies across tissues ( Figure 2D ). The C > G mechanism is more prevalent in bladder and breast cancer, while C > T dominates in lung adenocarcinoma and in cervical cancer (Figures 2D and S2I) . A3B is more prevalent in breast and lung adenocarcinoma, while A3A is important in bladder cancer and in squamous cell cancers of the head, neck, and lungs. The clustered mutation signatures furthermore suggest a certain level of A3 activity is prevalent across other tissues not commonly considered as A3 mutagenized, such as ovarian, prostate, pancreatic tumors, and melanoma (Figures 1F and S2I) .
A Signature of the Translesion Polymerase eta in Lymphoid Neoplasms
In addition to the A3 signatures C1-C3, the NMF algorithm discovered six further clustered mutation signatures ( Figure 1E ). Among them, signature C4 has the highest collective mutation burden in our tumor dataset (73% of signature C3; Figure 1F ). Signature C4 consists nearly exclusively of changes at A:T nucleotide pairs, of that mostly A > G changes primarily in the WA context, with additional A > C and A > T contributions, particularly at TA ( Figure 1E ). This NMF spectrum was also seen in the PC analysis (see above; Figure 1B ), and the two methods also converge on similar patterns of tissue specificity, highlighting lymphoma and chronic lymphocytic leukemia (CLL). Of note, some cancer types in which signature C4 is a minor contributor in relative terms ( Figure S2I ) still contain a substantial absolute load of C4 mutations, such as bladder cancer, melanoma and squamous cell cancers of the head and neck, and of the lungs ( Figure 1F ), which have a generally high clustered burden due to A3 mutagenesis.
The tissue-specificity of signature C4 toward lymphoid cells ( Figure 3A) suggests a link to somatic hypermutation (SHM), a physiological mutagenic process that diversifies immunoglobulin (IG) loci in B-lymphocytes. SHM is initiated by the cytosine deaminase AID, which can also act at off-target regions, broadly corresponding to promoters and enhancers of a subset of highly expressed genes (Wang et al., 2014) . The resulting uracils are repaired by a branch of the mismatch repair (MMR) pathway that recruits the error-prone DNA polymerase eta (POLH, encoded by the POLH / XP-V gene), which is the near-exclusive source of changes at A:T nucleotide pairs in SHM (Chahwan et al., 2012; Delbos et al., 2007) . Mammalian POLH is known to mutate the WA (TW) context and to preferentially cause A > G (T > C) over A > C (T > G) changes when copying undamaged DNA (Matsuda et al., 2000) , highly consistent with signature C4 ( Figure 1E ).
Indeed the relative preferences for 5 0 and 3 0 contexts at A:T pairs agree very well between signature C4 and the empirical estimates of SHM spectra from sequencing of human IG genes (Yaari et al., 2013) (Figures 3B and 3C; R = 0.91, 0.78 and 0.84 for A > C, A > G and A > T respectively), with overall R = 0.92 across all A:T mutations (adjusted for expected occurrence in same-mutation clusters; STAR Methods). In comparison, a previously observed lymphocyte-associated signature in a clustering-agnostic analysis (Alexandrov et al., 2013) exhibits only modest agreement to the known human SHM spectrum (R = 0.27 for all changes at A: T; Figures 3B and 3C) .
In addition to POLH, other DNA polymerases make minor contributions to the error-prone repair step of SHM; however, their GCN  TCN  ACN  CCN  GCN  TCN  ACN  CCN  GCN  TCN  AAN  CAN  GAN  TAN  AAN  CAN  GAN  TAN  AAN  CAN  GAN  TAN ACN  CCN  GCN  TCN  ACN  CCN  GCN  TCN  ACN  CCN  GCN  TCN  AAN  CAN  GAN  TAN  AAN  CAN  GAN  TAN  AAN  CAN  GAN 1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30  1  5  10  20  30 estimated clustered mutation burden, per Gb (D and E) Signature discovery using non-negative matrix factorization (NMF) from absolute counts of clustered and unclustered mutation spectra yields nine signatures with high confidence ( Figure S2 ) where clustered contexts predominate (above-diagonal in (D). In (E), NMF weights for six mutation types (tallied strand-symmetrically) broken down into 96 clustered contexts. known spectra are not consistent with signature C4. Therefore, we henceforth consider A > G clusters as a readout of POLH activity, noting that these mutations might still reflect, in part, activity of other cooperating error-prone polymerases.
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POLH-Signature Mutations Are Prevalent in Solid
Cancers and Enriched at the 3 0 End of Active Genes We investigated whether the POLH-spectrum mutations are targeted in a similar manner in solid tumors as they are in lymphoid cells. We focused on tumors that exhibit a burden of signature C4 in the range normally observable in lymphocytes ( Figure 3A ; above the tenth percentile of lymphoma+CLL samples; estimated $2.5 clustered single-nucleotide variants (SNVs) per gigabase generated by C4; STAR Methods). Notably, the median C4 burden in many solid tissues is close to, or exceeds that threshold ( Figure 3A ; highest in melanoma, liver, and bladder).
In lymphoid cells, AID, a prerequisite for the subsequent POLH activity during SHM, is known to be directed toward a particular set of highly transcribed regulatory elements (Wang et al., 2014) . Consistently, we find that these known AID off-target regions (STAR Methods) are 90.4-fold enriched with A > G clustered mutations in lymphoid neoplasms ( Figure 3D ). Examining the solid tumors, however, we found no enrichment of clustered A > G in AID off-targets ( Figures 3D; 1 .18-fold, 95% confidence interval [CI] 0.59-2.36) indicating differential targeting mechanisms. Of note, the IG genes were only modestly enriched with A > G clusters in solid compared to blood tumors (150.4-fold difference between the groups; Figure 3D ), ruling out a prevalent lymphocyte infiltration in these solid tumor samples.
In lymphoid cancers, 34%-51% of the clustered A > G mutations at known AID targets and other active chromatin regions have a C:G pair mutation within 100 bp ( Figure S3A ), consistent (A) NMF weight of signature C3 correlates to A3A expression more than to other APOBECs, and signatures C1 and C2 to A3B. p values by Z-test on Fishertransformed Pearson correlation.
(B) Context of the cytosine mutations at TpC in tumors in which signature C1 (left column, n = 92), C2 (middle, n = 127), or C3 (right, n = 56) is prevalent (criteria same as that used in Figure S2I ; > 40% relative NMF weight per tumor) reveals a A3B-like RTC context in C1/C2 tumors, but an A3A-like YTC preference in C3 tumors (Chan et al., 2015) . All shown nucleotides are significant by t test (p < 0.05, Bonferroni adjusted). (C) Distances between pairs of A3 mutations of the C > T versus C > G type; sample groups are the same as those used in (B).
(D) Classification of the common A3-mutagenized cancer types into A3B-class and A3A-class (x axis); and, independently, into C > T-class and C > G-class (y axis). Points are medians; whiskers are at the first and third quartiles. See also Figure S2 .
with AID initiation. However, in solid tumors with a high level of signature C4, there is no evidence for initiation by AID or another mutagen acting at C:G nucleotide pairs (0%-9% in the same set of regions; Figure S3A ). We further analyzed the targeting of clustered A > G changes using an 18-state chromatin segmentation scheme (STAR Methods). In lymphoid cells, A > G clusters were enriched in transcription start site and active enhancer states ( Figure S3C) , consistent with the known patterns of AID off-targeting (Wang et al., 2014) . In contrast, in the C4-high solid tumors ( Figure 3A) , A > G clusters are most enriched in open chromatin states associated with transcribed gene bodies ( Figure S3C ). Consistent with this, the clustered A > G mutations are enriched toward the 5 0 end of genes in lymphoid tumors but toward the 3 0 end of genes in solid tumors, peaking at the transcription start site and end sites, respectively ( Figures 3E and S3B ).
POLH-Spectrum Mutations Target Different Chromatin
States in Lymphoid and Solid Tissues Next, we imposed more stringent clustering criteria by limiting the distance to %100 nt (this captures the majority of POLH-spectrum clusters; Figure 3F ) and considering only A:T (B and C) Spectrum of C4 (middle) agrees closely with somatic hypermutation (SHM) at A:T pairs (top) known to result from activity of DNA polymerase eta (POLH) (Yaari et al., 2013) . Signature 9 is a previous lymphoma-associated non-clustered signature (bottom) (Alexandrov et al., 2013) . ( nucleotide pairs. Due to a lowered FDR (estimated via randomization; STAR Methods), more high-mutation-burden tumors could be considered ( Figure S5A ), revealing, for instance, prevalent mutation clusters at A:T pairs in many melanoma samples ( Figure 3G ). Repeating the NMF discovery recovered the original A:T-pair signatures C4, C8, and C9, and two others (Figures S5B and S5C) . In total, we further examined a total of 1,481 tumors with clustering FDR %20% and R5 clustered changes at A:T sites, ignoring IG loci ( Figure S5A ). We systematically surveyed the association of the POLHspectrum-clustered mutations to chromatin marks, gene expression levels and 5 0 versus 3 0 gene ends. An unbiased approach using a PC analysis of clustered mutation density across genome regions (STAR Methods) reveals two divergent ways in which A > G clusters can be targeted at open chromatin (Figures 4A and S4C) . Broadly, these correspond to H3K4me3 and H3K27ac-marked regions in lymphoid cells and to 3 0 gene ends, high transcription levels, and the H3K36me3 mark in solid tissues (Figures 4B, S4D, and S4E) .
Histone modifications associated with active chromatin, including H3K36me3, co-occur across the genome and, moreover, correlate with known determinants of somatic mutation rates: replication time (Supek and Lehner, 2015; Woo and Li, 2012) , transcription levels (Pleasance et al., 2010; Zheng et al., 2014) , and chromatin accessibility (Polak et al., 2014; Schuster-Bö ckler and Lehner, 2012) . We used negative binomial regression (STAR Methods) to estimate the independent contribution of each variable toward enrichment of A > G clusters in the solid tumors with high clustered A > G burden and prominent targeting at 3 0 gene ends/H3K36me3 (n = 375; Figures S4D and S4E ). Controlling for replication timing, we observed a 3.54-fold enrichment of the A > G clusters in the highest H3K36me3 quintile, relative to unclustered A > G mutations (95% CI 2.91-to 4.30-fold; Figure 4C ), and similarly so when adjusting for DNase hypersensitive (DHS) sites as a general measure of open chromatin (3.50-fold enrichment; Figure S4F ).
In contrast, the general set of unclustered A > G mutations ( Figures 4C and S4F ) and, more broadly, all mutations ( Figure 5D ) are depleted from H3K36me3-regions, even after accounting for the effects of replication time and DHS; breakdown per mutation type in Figure S6A . This suggests that H3K36me3-marked chromatin has a lower somatic mutation rate.
We further controlled for expression levels and additional open chromatin marks ( Figures 4D and S4F ), including two additional modifications associated with transcribed gene bodies (H3K79me3 and H4K20me1, Figure 4E ). A high enrichment (2.35-fold over unclustered A > G, 95% CI 2.03-2.73) is observed in the top H3K36me3 bin ( Figure 4E ; the definition of bins is provided in the STAR Methods). Therefore, H3K36me3 is a genomic feature strongly and independently predictive of POLH-spectrum clustered mutagenesis.
Targeting of POLH-Context Mutations at Active Genes Depends on Active MMR
The mutations at A:T pairs that occur during SHM in B-lymphocytes depend on a functional MMR pathway to recruit POLH to the initial AID lesion; reviewed in (Chahwan et al., 2012) . ''Noncanonical MMR'' (ncMMR) utilizing POLH can also be recruited to chromatin in non-lymphoid cells by various genotoxic insults, e.g., via methylating and oxidizing agents (Peñ a-Diaz et al., 2012; Zlatanou et al., 2011) . Moreover, the H3K36me3 mark can recruit the (canonical) MMR machinery via binding of the MSH2-MSH6 complex (Li et al., 2013) , which is also a component of the POLH-utilizing, ncMMR pathway. MMR thus provides a plausible mechanistic basis for directing both error-free and error-prone DNA synthesis toward H3K36me3 chromatin.
We tested whether functional MMR activity is necessary for observing clustered A > G changes by using MMR-deficient solid tumors identified by microsatellite instability (MSI). MMRdeficient tumors from the colon, uterus, stomach, liver and breast all have a striking decrease in the A > G clustered changes up to 50 nt relative to a control set of nearby A > G mutations at 51-500 nt ( Figure 5A H3K36me3 Is a Target for Both Canonical and ErrorProne MMR Next, we analyzed tumors with mutations in SETD2, a methyltransferase that deposits the H3K36me3 mark (Edmunds et al., 2008) and is commonly altered in kidney cancer (Kanu et al., 2015) . We observed that kidney and liver cancers with homozygous deletions or nonsynonymous mutations in SETD2 have no significant targeting of the A > G clusters toward normally H3K36me3-rich regions, in contrast to the remaining tumors from the same studies (adjusted for replication time in Figure 6C ; for other confounders in Figure S3H ). Therefore, both SETD2 and functional MMR are necessary for occurrence of A > G clusters in H3K36me3 regions. These observations converge onto a model where POLH/ncMMR is preferentially recruited to H3K36me3-rich regions, leaving behind a recognizable A > G clustered signature observed in a variety of human cancers.
Crucially, the relative depletion of unclustered A > G mutations in H3K36me3 regions is also considerably reduced in MMRdeficient genomes ( Figure 5B ). Moreover, this MMR-dependent depletion is observable across various non-clustered mutation types and tissues-of-origin, regardless of replication time or DHS ( Figures 5D and S6A ). This provides important genomic evidence that MMR activity is directed toward H3K36me3 in human somatic cells, reducing the mutation rate in these regions. Recruitment of the MSH2-MSH6 complex by H3K36me3 provides a likely molecular mechanism (Li et al., 2013). We estimate that H3K36me3 has a quantitatively larger effect on somatic mutation rates than DHS, but a lower effect than replication timing, which is the predominant influence (Figure 5D ). In addition to abolishing the H3K36me3 effect, the MMR deficiencies also remove the effect of replication timing, as we have shown previously (Supek and Lehner, 2015) and we extend here to additional cancer types (liver and breast; Figure 5D ). However, defective MMR does not reduce the DHS effect ( Figures 5D and S6A) .
The regional enrichment of clustered but depletion of unclustered A > G mutations therefore implies that H3K36me3 chromatin is targeted by both error-free (canonical) MMR and error-prone ncMMR involving POLH ( Figure 5B, right panel) . However, the differences in clustered A > G load across individual tumors suggest that the relative balance between error-free and error-prone repair-both directed at H3K36me3-varies across cell types.
Error-Prone Repair Likely Generates Substantial Numbers of Unclustered Mutations
The short length of the POLH-signature mutation clusters (Figure 3F) suggests that the same process may also generate many singleton mutations at A:T. This would imply that the rate of clustered A > G changes predicts the rate of unclustered mutations at the same contexts. To investigate, we normalized the A > G burden (both clustered and unclustered) to the tally of all mutations at C:G pairs in a given tumor sample to compensate for the accumulation of mutations with time (STAR Methods). Indeed, this reveals robust correlations between the rates of clustered and unclustered A > G (example tissues in Figures 6A and S6B ; individual studies shown in Figure S6F ). The clustered A > G rates also predict the other two changes at A:T pairs (example in Figure S6C ), suggesting that the same mutagenic process also contributes non-negligible amounts of mutations toward the overall tally of the A > C and A > T.
The regression fits provide an estimate of the contribution of the putatively POLH-driven mutagenesis to the overall mutation burden at A:T pairs in a cancer type (caveats discussed in STAR Methods; example in Figure 6A ). This analysis suggests a substantial mutagenic contribution of POLH, constituting 53%, 44%-61%, 81%, and 53% of all changes at A:T pairs in colorectal, stomach (two studies), bladder and head and neck cancer, respectively ( Figures 6B and 6C ). Strikingly, in melanoma at least two-thirds of all A:T mutations are predicted to result from POLH mutagenesis (65%-82% across three independent studies; Figures 6B and 6C). The absolute contribution to liver cancer mutations is also substantial (Figure S6E ), but less so in relative terms due to another process that generates unclustered A > G (at NAT trinucleotides; signature A:T-1 in Figures S5B and S5C ) as previously reported, e.g., Fujimoto et al. (2016) . Other cancer types, such as ovarian or prostate tumors exhibit modest POLH contributions ( Figure 6B ). Across cancer types and studies, the relative contribution of POLH toward mutations at A:T pairs correlates to the absolute burden at A:T (r 2 = 0.379; Figure 6C ), consistent with error-prone DNA synthesis contributing substantially to differences in the overall somatic mutation burden between tumors.
The Shifting Balance between H3K36me3-Directed Repair and H3K36me3-Directed Mutagenesis If the excess unclustered mutations in POLH contexts are indeed caused by ncMMR, one would expect their preferential distribution toward H3K36me3 chromatin. Upon examining how the H3K36me3-enrichment of unclustered mutations for individual tumors (STAR Methods) changes with the increasing rates of A > G clusters-a marker of ncMMR activity-we observe a significant positive correlation across solid cancers (r 2 = 0.214; Figure 6D) . This trend is also evident in the (generally rarer) A > T and A > C changes ( Figure S6G ), where the ncMMR also makes an important relative contribution ( Figure S6D ). In contrast, this effect is absent in lymphoid tumors ( Figure 6D ; r 2 = 0.001), where the clustered A > G are targeted at promoters and enhancers ( Figures 4D and S4F ).
In the solid tumors that exhibit targeting toward H3K36me3, the lowest 20% of tumors by clustered A > G rate displays a 1.68-fold depletion of unclustered changes at A:T in the H3K36me3 regions (a definition is provided in the STAR Methods; Figure 6E ), after controlling for replication time. In contrast, the top 20% by clustered A > G rate exhibits no significant depletion (1.04-fold). This suggests that a high level of ncMMR activity shifts the net balance of processes in H3K36me3-marked chromatin away from repair and toward mutagenesis. Therefore, error-prone DNA repair provides a broadly acting source of mutations preferentially targeted at the 3 0 ends of active genes. We do not observe an overall targeting of A > G clusters toward H3K36me3 in lymphoid tumors, when considered jointly ( Figures 4D and 4E ). Conceivably, AID mutagenesis focused toward promoter/enhancer regions in physiological SHM (Wang et al., 2014) may redirect the ncMMR activity away from 3 0 gene ends. Indeed, the targeting toward H3K4me3/H3K27ac is anti-correlated to targeting toward H3K36me3 across individual lymphoid tumors, and we observe this in both CLL and in B cell lymphoma ( Figure S3D ). In lymphoid tumors with a low mutation enrichment in H3K4me3/H3K27ac regions, the H3K36me3 is, in fact, significantly enriched with A > G clusters (2.20-and 1.85-fold over unclustered, for CLL and lymphoma, respectively; Figure S3E ). Therefore, the data are consistent with a mechanism where the retargeting of POLH toward the 5 0 of genes by SHM reduces the default targeting to the 3 0 end of genes.
UV-Triggered POLH Mutagenesis Generates Driver Mutations in Melanoma
The level of clustered POLH-spectrum mutagenesis, as well as the associated increase in general mutation rates at H3K36me3, appears higher in some tumor samples than in others. Past work has shown that various mutagenic insults recruit ncMMR components, including POLH, to chromatin (Peñ a- Diaz et al., 2012; Zlatanou et al., 2011) . We thus hypothesized that mutagen exposure might be associated with higher levels of POLH-spectrum mutation clusters.
Melanoma is the archetypal cancer caused by an external mutagen-UV light-and our analyses suggest a high contribution of POLH to the overall A:T mutation burden therein (Figures 6C and S6F) . A mechanistic basis for this is provided by the wellknown POLH-mediated bypass of UV lesions in mammalian cells (Yang and Woodgate, 2007) . UV light creates a unique signature of otherwise extremely rare CC > TT dinucleotide substitutions (Brash, 2015; Chen et al., 2013) . We found that the burden of clustered A > G changes correlates to the burden of CC > TT across independent melanoma studies (r 2 = 0.25-0.46; Figure 7A) , suggesting that indeed error-prone DNA synthesis triggered by UV might provide an abundant source of mutations at A:T pairs in the skin. Although mutations at C:G predominate in melanoma, the majority of driver mutations in the important oncogenes BRAF and NRAS occur at A: T pairs (Hodis et al., 2012) . Based on our estimate that 65%-82% of A:T changes in melanoma are POLHrelated ( Figure 6C ), POLH may be a potential source of these oncogenic mutations. In support of this, melanoma samples harboring a missense BRAF or NRAS mutation have a significantly higher clustered A > G burden (p = 0.034 and 0.031, respectively; by Mann-Whitney test, one tailed; Figure 7B ) than BRAF/NRAS wild-type tumors. If further validated, this would provide an example of error-prone DNA polymerases producing oncogenic driver mutations when triggered by an external DNA damage source.
POLH Burden and H3K36me3 Targeting Is Associated with Alcohol Consumption in Liver Cancer
Another tissue that commonly exhibits POLH-signature-clustered mutations (Figures 1F and S2I) targeted at H3K36me3 regions is the liver ( Figure S4E ). Liver cancer is strongly linked to environmental factors, including hepatitis infection, alcohol consumption and smoking. Using a well-annotated genome sequencing study of liver hepatocellular carcinoma (Fujimoto et al., 2016) (n = 240; STAR Methods), we applied regression to estimate independent associations of clinical covariates to POLH signatures. First, we examined the contribution to the overall abundance of clustered A > G mutations, observing a significant association with alcohol consumption (p = 0.004 and 0.029 at high consumption levels; 1.59-and 1.54-fold increase; Figure 7D ) but not with other risk factors ( Figure S7A ).
Next, we asked whether the targeting of clustered A > G toward H3K36me3-high genome regions is associated with the clinical covariates (STAR Methods), again finding an association with alcohol (p = 9 3 10 À6 to 0.045; 1.30-to 1.85-fold enrichment; Figure S7B ). The only other covariate significant in both tests was gender (Figures S7A and S7B) , which might reflect gender-specific liver responses to mutagens (Naugler et al., 2007) or other biases. Interestingly, in patients that consumed alcohol, unclustered A > G changes were also preferentially directed toward H3K36me3 regions ( Figure S7B ; p = 8 3 10 À5 , 1.19-fold enrichment). Therefore, even in the absence of an overt increase in A > G mutation burden, differential targeting toward expressed genic regions provides a possible basis for the carcinogenic effects of alcohol.
Alcohol and Other Carcinogens Are Associated with POLH-Spectrum Burden in Multiple Cancers
In addition to liver, a positive association between alcohol and A > G clusters was seen in other cancer types with known links to alcohol consumption: esophageal, head and neck, and pancreatic cancers ( Figures -------known alcohol-associated cancers ---------not alcohol-associated --- (D and E) The overall burden of A > G clusters is associated with high alcohol intake in cancer types known to be linked to alcohol consumption (D), but not in other cancers (E) . Log enrichments are coefficients and 95% CI from a negative binomial regression (as base 2). Individual studies and all covariates adjusted for are in Figure S7 . Significance levels are FDR-adjusted (q-value, shown as a percentage). (F) In tobacco smoking-linked cancers, the statistical association of clustered signatures to the smoker / never-smoker status was expressed as the area under the curve (AUC) score. Additionally, S4 and S5 are known non-clustered mutation signatures of smoking. (G and H) Total clustered C5, C7, and C9 burden separates ever-smokers from never-smokers in three cancer types (G) and shows an association to pack-years smoked therein (H); p value by randomization test for trend.
(I) Summary model. See also Figure S7 .
weekly alcohol consumption showed associations while social drinking did not, suggesting a possible dose-response effect ( Figure 7D ). In contrast, we observed no evidence of alcohol consumption-related mutagenesis in four cancer types in which alcohol is known not to be an important risk factor: melanoma, prostate, neuroendocrine tumors of the pancreas, and CLL (pooled p = 0.46; Figure 7E ). Alcohol consumption is often confounded with other lifestyle factors, such as smoking; when data were available, our analyses adjust for this (see Figure S7) . Nevertheless, epidemiological studies with larger WGS sample sizes are warranted to provide further support for the role of alcohol in mutagenesis. In addition, the A > G cluster burden was associated with heavy tobacco smoking in urinary tract cancers (p = 0.016; 3.05-fold enrichment; Figures S7F and S7G ), but not in lung cancers (Figures S7F and S7G) . This suggests that tobacco metabolites but not direct exposure to smoke may increase repair by POLH. The non-clustered mutation signatures are known to differ between these two types of exposures (Alexandrov et al., 2016) . Esophagus and pancreatic cancers show marginally significant trends ( Figures S7C-S7E) .
We found indirect evidence that exposure to another mutagen might trigger error-prone repair in esophageal adenocarcinoma (ESAD), which often exhibits a high load of an unusual A > C signature, mostly in the AAG context (Nones et al., 2014) . The proposed mechanism involves oxidative stress caused by gastric reflux, which generates free 8-oxoG (Dvorak et al., 2007) that, following incorporation into DNA, results in A > C changes. Given that POLH appears involved in such mutagenesis (Satou et al., 2009), we searched for a genomic imprint of POLH in ESAD tumor genomes. Indeed, the rate of unclustered A > C at AAG predicts the rate of clustered A > G at the non-overlapping TAH (H = not G) context ( Figure 7C ; both normalized to total burden at C:G pairs). This provides genomic evidence for a hypothesized mechanism where oxidized G in the free nucleotide pool triggers mutagenesis not only via the known mechanism of misincorporation into DNA but also indirectly, via error-prone DNA polymerases (Satou et al., 2009) .
Hypothesized Mechanisms for Two Other Widespread Clustered Mutational Signatures
After the POLH signature C4, the following two most prevalent processes are signature C7 (44%) and signature C5 (43% of the NMF weight in our data, relative to the most abundant signature C3; Figure 1F ). Signature C7 consists of C > T changes preferentially in the RC context (R is a purine) and a subtle contribution of C > G changes. This spectrum and the abundance of C7 in lymphoma ( Figure S2I ) suggest that C7 might reflect activity of the AID cytosine deaminase or a similar process. This signature is, intriguingly, also common in many solid tissues (Figures 1F and S2I) and is enriched in promoters therein (2.90-fold over unclustered changes in H3K4me3 chromatin; Figure S7N) , which is unlikely to result from infiltrated lymphocytes ( Figure S7M ).
Signature C5 consists of R > T transversions, meaning that either purine gets substituted by a thymine. This unusual spectrum is consistent with depurination events, where the resulting abasic sites are bypassed by inserting an adenine across, according to the ''A-rule'' (Pagè s et al., 2008) . C5 is widespread in the ovary, uterus, and stomach and in lung adenocarcinoma, where its median burden matches or exceeds APOBEC ( Figures 1F and S1F ). One cause of such spontaneous depurination is bulky adducts on purine bases. We therefore systematically examined the association of C5 and the other signatures with tobacco smoking.
Clustered Mutational Signatures Are Robustly Associated with Tobacco Smoking
Indeed, the burden of signature C5 is robustly increased in smokers in lung, kidney, and head and neck cancers (FDR > 10%; Mann-Whitney test, one tailed; Figure S7I ). Of the previously determined general (non-clustered) signatures, two are known to be associated to tobacco smoking, signature 4 and signature 5 (henceforth, S4 and S5) (Alexandrov et al., 2016) . They have a distinct spectrum from clustered signature C5 (Figure S7H) , suggesting different underlying mutagenic pathways. After estimating S4 and S5 in our set of 1,159 tumors (STAR Methods), we found that the association of signature C5 with smoking is similarly supported (mean AUC = 0.63 across the eight tested cancer types) as for S4 and S5 (0.62 and 0.61, respectively; Figure 7F ). Additionally, an association is observed for Signatures C6 and C9 ( Figure 7F ), which consist of C > A and A > T changes, respectively ( Figure 1E ), suggesting that that they might represent subtypes of C5, where DNA damage or repair is preferentially directed toward A:T or C:G pairs in a tissue-specific manner ( Figure S2I ; smoking associations per tissue in Figure S7I ). Of note, C5, C6 and C9 are common in some tissues where they are unlikely to result from smoking, illustrating how different DNA lesions may initiate the same downstream mutational outcome.
In the tissues where C5 burden was increased in eversmokers, we also observed a suggestive relationship to the number of pack-years (p = 0.04 for C5, randomization test for trend across three categories; Figure S7J ). Similar trends consistent with a dose-response relationship were seen for C6 and C9, with comparable support to non-clustered signatures S4 and S5 ( Figure S7J ; sum of C5, C6, and C9 in Figures 7G and 7H ). We thus further tested the predictive power of clustered versus non-clustered smoking signatures to discriminate non-smokers from moderate or heavy smokers in a cross-validation test (STAR Methods). The clustered signatures predict smoking status 57% and 51% accurately on tissues with direct and with indirect exposure, respectively, exceeding the 45% and 43% provided by the non-clustered signatures S4 and S5 ( Figures  S7K and S7L ). This illustrates how mutation clusters can yield a reliable historical record of mutagenic exposures an individual has undergone.
DISCUSSION
We have shown here that diverse mutational processes generating clustered single-nucleotide changes operate in human somatic cells. In addition to variable initiation and processing in APOBEC3 mutagenesis at C:G nucleotide pairs across tissues, our results suggest that error-prone DNA repair involving POLH commonly creates both clustered and unclustered mutations at A:T nucleotide pairs in many cancer types.
Our analyses reveal that H3K36me3 chromatin is normally protected from somatic mutations because of increased MMR activity, which is consistent with the ability of the H3K36me3 mark to recruit the canonical MMR machinery (Li et al., 2013) . Accounting for this additional factor shaping mutation rates at 3 0 gene ends may prove important for methods that detect selection on somatic mutations in oncogenes or tumor suppressors.
However, exposure to some carcinogens results in increased activity of a non-canonical, error-prone, MMR pathway involving POLH (Peñ a-Diaz et al., 2012; Zlatanou et al., 2011) , which results in an increased relative mutation rate in H3K36me3-marked regions (schematic in Figure S7O ). This suggests that some environmental factors act as carcinogens not because they necessarily increase the overall mutation rate but because they redistribute mutations to the more important regions of the genome.
For example, alcohol is a well-established cancer risk factor, but the mechanisms underlying this are surprisingly unclear. Our data suggest that one effect of alcohol may be to increase the relative mutation rate in active regions of the genome because of increased error-prone DNA repair.
Our analyses are consistent with error-prone repair contributing a substantial general mutation load at A:T pairs, particularly in melanoma, gastrointestinal tract cancers, bladder cancer, squamous cell carcinoma of the head and neck, and lung cancer ( Figure 6B ). Moreover, these mutations, because they target active genes, are also more likely to be consequential. UV damage primarily results in C > T changes, but the highest frequency cancer-causing driver mutations in melanoma (in BRAF and NRAS) are actually often at A:T pairs. Our data suggests a possible origin of these drivers: UV damage does not directly cause the driver mutations but, instead, it is the error-prone bypass of UV lesions that creates the oncogenic mutations in NRAS and BRAF.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
This publication describes statistical analyses performed on human cancer genome data obtained from various sources (see Method Details). REAGENT 
METHOD DETAILS Somatic mutation data
We collected somatic single-nucleotide variants (SNVs; henceforth, mutations) called from whole-genome sequences (WGS), immediately discarding tumor samples with a mutation burden that was either very low (< 150 total mutations in genome) or very high (ultra-mutated tumors with > 100 mutations/Mb). The WGS were collected from various sources: (i) We used a set of WGS (n = 733) from The Cancer Genome Atlas (TCGA), which largely overlaps with those used in our previous work (Supek and Lehner, 2015) and was processed in the same way. Briefly, the BAM files with aligned short reads from the CGHub repository were used to call somatic mutations in the hg19 assembly using Illumina's Strelka 1.0.6. We further increased call stringency by requiring very low numbers of filtered or gapped reads at the mutated site: BCNoise < 3% and SpanDel < 3% for the tumor and < 10% and < 10% for the normal tissue (defaults were < 40% and < 75%, respectively). For extremely high-confidence calls (QSS_NT R 45), BCNoise of up to 6% is exceptionally allowed for the tumor. 5 , 6, 7, and S5) were downloaded from ICGC v20 as LIRI-JP and LINC-JP; a subset of these liver tumors was already provided within the Alexandrov et al. (Alexandrov et al., 2013) repository (see above; identifiers starting with HX and RK) and these same samples were not further added from ICGC.
Calling mutation clusters
As previously (Supek and Lehner, 2015), we excluded all UCSC blacklisted regions in hg19 (Duke and DAC) and additionally excluded difficult-to-align genome regions via the 'CRG Alignability 36' track. The latter is a stringent filter, requiring 36-mers in the genome to be unique even after allowing for two mismatching nucleotides, leaving 1.9 Gb of alignable DNA in hg19. This filter is applied to all subsequent analysis in our work (with a single exception: see section ''Somatic hypermutation target regions'' below). Mutations in these alignable regions are sorted into the clustered and the unclustered class (with some mutations remaining unsorted), based on the following criteria for clustered mutations: (a) % 500 bp distance between two mutations in a cluster; (b) strand-coordination, meaning that both cytosines (for C:G pairs) or both adenines (for A:T pairs) must be on the same strand; (c) both mutations must be of the same type, for instance C > G clusters only with other C > G; (d) unclustered mutations must be at least 10kb apart. Pairs of directly adjacent single-nucleotide variants, which may commonly reflect a tandem substitution event, were not considered in our set of clustered mutations for signature discovery, as they were previously cataloged in human cancer genomes (Chen et al., 2013) and are likely to be generated by processes distinct to those producing clusters at R 2 nucleotides apart. The clustering criteria above (%500 bp, strand-coordinated, same mutation, all alignable genomic sites) were used for the general clustered mutation discovery and the APOBEC analysis. In further analyses, we employed a more stringent set of clustering criteria that is appropriate for detecting putative POLH clusters: requiring % 100 bp distance and limiting only to A:T alignable sites in the genome; the DNA strand-coordination requirement was retained. In addition, here we allowed the clusters to consist of different kinds of mutations, since POLH could conceivably create A > G and A > T/A > C changes in a single run. These criteria resulted in lowered false discovery rates, allowing us to expand the set of considered tumor samples (compare Figure S1C to Figure S5A ; these panels show the same set of tumor samples in the same order).
Clustering false discovery rates
To determine false discovery rates (FDRs) for clustered mutations in a tumor sample, we employed a randomization test that controls for the megabase-scale variability in mutation density and in G+C content of DNA. First, mutation clusters are called in a tumor sample using the criteria above. Then, the coordinates of the mutations are randomized by shifting every mutation by a random distance within ± 500 kb. Mutations at A:T pairs are moved to any other A:T (and C:G to C:G) while additionally allowing the DNA strand to be flipped. Only the alignable genomic regions (by the ''CRG36'' track, see above) may receive the randomized mutations. After shifting each mutation, the mutation clusters are re-called using the same criteria, and these random clustered mutations tallied. This is repeated five times per genome and the median number of clustered mutations of these iterations is an estimate of the expected clustered mutation tally, given the overall mutation burden and regional rates in that tumor sample. Dividing the expected by the observed number of clustered mutations in the actual (not randomized) genome yields the FDR.
To obtain the 1159 WGS set used for the clustered signature discovery using the PCA and non-negative matrix factorization (NMF) methods ( Figure S1C ), we required R 10 clustered mutations per genome and % 20% clustering FDR for individual genomes (distances % 500 bp, at both A:T and C:G nucleotide pairs). We manually inspected the aligned short reads for tumor samples with a high clustered mutation burden and for which the BAM files were available; we found six genomes where the clusters were in regions with strong strand biases of reads, and we also observed sudden drops in read coverage near the mutation clusters. As a precautionary measure, we excluded these six samples (UCEC_TCGA-B5-A11I, BRCA_TCGA-B6-A0I6, BRCA_TCGA-AO-A0J6, BRCA_TCGA-A2-A0CM, BRCA_TCGA-A2-A04P, BRCA_TCGA-AO-A0J4). Furthermore, in the ICGC study SKCA-BR (melanoma), we found several samples with a high level of the CAC > CCC unclustered signature, which is unusual for melanoma and moreover has previously been suggested to be an artifact (Signature R1 in (Alexandrov et al., 2013) ). To obtain the final 1159 WGS set, we therefore also excluded these 10 samples (SA553005, SA545527, SA545539, SA545469, SA552996, SA545493, SA553000, SA553006, SA545537, SA545517).
The pooled FDR estimate across the dataset was obtained by summing the number of clustered mutations across all 1159 WGS samples randomized, dividing by the sum of clustered mutations in actual genomes; this yields a pooled FDR of 4.8%. To obtain the 1481 WGS set used for the A:T pair-specific analyses (Figures 4, 5, 6 and 7) , we required R 5 clustered mutations at A:T per genome and % 20% FDR for individual genomes (with % 100 bp distance); overview of false discovery in Figure S5A . In this A:T-only data, the pooled clustering FDR = 5.2%.
Evidence that mutation clusters derive from a single event In order to provide a further, independent estimate of false discovery of mutation clusters, we examined the distribution of the variant allele fraction (VAF) of the mutated alleles in 409 of 1159 WGS samples where this data was available to us (those where we called mutations from the TCGA WGS set using Strelka, see above). The VAF is simply the percentage of sequencing short reads in each locus that reports the somatic mutation-for germline variants, VAFs are either close to 50% (heterozygous) or 100% (homozygous) but for somatic variants they can span a whole range of values, depending on the time when a mutation happened during carcinogenesis. Broadly, earlier-occurring mutations have higher VAFs and later-occurring ones have lower VAFs. We compared the observed distributions of the absolute log 2 ratios of VAFs (VAF LR ) of mutation pairs within a cluster to a positive control VAF LR distribution and a negative control VAF LR distribution, for mutation clusters of a given type: we analyzed separately the TCW > T[TG]W, A > G, C > A + A > T, RC > RT mutations, and all remaining contexts pooled together (these categories correspond to the mutation signatures discovered by NMF; see below).
The positive control was an idealized distribution that would be obtained with fully equal VAFs, accounting for stochastic noise due to limited read counts, which we estimated via simulation that considers the read coverage at each called mutation. In other words, at very high sequencing coverage, the absolute VAF LR value for a genuine mutation cluster will tend toward 0, but not so at low coverages where the estimates of the VAF are noisy. Importantly, at very short clustering distances, this noise will be much smaller than expected by the simulation, since two mutations are spanned by exactly the same reads, meaning their occurrences in the sequencing data are not independent events. We estimated the fraction of such shared reads by two mutations at distance x as (50-x)/(50+x), and adjust the VAF LR distribution such that this fraction with shared reads has VAF LR exactly = 0.
The negative control was an empirical distribution observed with non-clustered mutations that still lie within a 1Mb distance, thereby accounting for confounding effects of regional copy-number alterations on VAF. Next, we modeled the observed, actual VAF LR distribution as a mixture of the positive control and the negative control VAF LR distributions. We binned the data for all three distributions (observed and two controls) into five equal bins from VAF 0.0 to 0.5, and an additional sixth bin for VAF > 0.5, as depicted in Figure S2G . These six points per distribution were used to find a linear fit (the lm function in R) that predicts the observed VAF LR distribution from the two controls. Then, the FDR estimate for the mutation clustering was found from the regression coefficients, as coef NegCtrl / (coef NegCtrl + coef PosCtrl ). For all five considered mutation types (see above), R 2 of fits was > 0.98. Importantly, using VAFs to determine FDRs of clustered mutations in this manner is conservative, since it assumes that the clustered mutational process under scrutiny is not highly focused to specific locations of the genome. If it were, it could generate independent but nearby mutations at different times during tumor evolution. In other words, mutations from distinct events would be close enough (distance % 500 bp) to be considered a single cluster, thereby biasing the observed distribution of intra-cluster VAF differences toward larger values and consequently providing a pessimistic FDR estimate. One example is SHM in B-lymphocytes, where AID mutagenesis is directed toward the promoter regions of IG genes and a small number of off-target regions that tend to be several kb long. If AID contributes mutations in IG gene promoters for extended periods of time, it would generate spurious clusters that consist of a mix of earlier and later mutations and have different VAFs. Conceivably, the same effect could be evident to some extent also with the POLH (Signature C4) mutation clusters that are preferentially directed toward H3K36me3-high regions in solid tumors.
Mutational signature analysis using PCA and NMF We inferred mutational signatures on clustered and on unclustered mutations simultaneously. We separated both sets of mutations in each tumor sample into 6 mutation types (C > A, C > G, C > T, A > C, A > G, A > T; due to strand symmetry, these are equivalent to G > T, G > C, G > A, T > G, T > C, T > A, respectively), and each of those into four 5 0 and four 3 0 nucleotide contexts. In total, this yields 96 clustered and 96 unclustered mutation contexts for each tumor. The unclustered mutations were subsampled to match the number of clustered mutations in each tumor, thereby making it possible to estimate the relative contributions (per mutation) of the clustered and the unclustered part of the spectrum toward each mutational signature. For the PCA analysis, the mutation counts in the 96+96 contexts were normalized to relative frequencies (summing to 1.0) within each tumor sample. Therefore, each of 1159 analyzed tumors have an equal contribution toward the PCA, irrespective of their clustered mutation burden (all had R 10 clustered mutations, see above). In other words, this PCA highlights the mutational signatures that are consistently observed across a large number of tumor samples.
The NMF analysis used a methodology similar to that described previously (Alexandrov et al., 2013) . In particular, absolute mutation counts for the 96+96 contexts per tumor sample were used, i.e., without normalizing to relative frequencies within each tumor sample. Furthermore, bootstrap sampling of mutations (n out of n from each tumor, with replacement) was applied to this table to make 200 resampled tables with mutation counts, which contain both the 96 clustered and 96 unclustered spectra side-by-side. On each of these 200 tables, NMF was run using the function nmf in the R package NMF version 0.20.6, with maxiter = 10000, the rank parameter (number of extracted factors) varying from 2 to 10, and other parameters left at default (thus using the 'brunet' algorithm). The seed for the random number generator is changed before every NMF run. For each value of rank, the NMF factors (extracted from the H-matrix) from all of the 200 NMF runs are further processed together. In particular, they are clustered using the k-medoids algorithm (the pam function in R package cluster) using different values of k; the same function also provides the silhouette index (SI) for the clusters, which is the average SI of all NMF factors within each cluster ( Figure S2 ). SI is a clustering quality measure and higher values thereof signify a higher consistency of the clustering solution (here, a set of mutational signatures) across repetitions of the bootstrap sampling. The minimum SI across all clusters is used to guide the selection of the number of NMF factors and clusters (7 and 9, respectively). The medoids of these clusters are then the mutational signatures, which have a clustered part (in Figure 1E ) and an unclustered part (in Figure S2F) . Tumor samples from all cancer types and studies are analyzed jointly. The contributions of the 9 NMF signatures toward the clustered mutation burden (as SNV/Gb, Figure 1F ) were estimated as follows: first, the relative contributions of the 9 signatures were determined for each tumor sample by dividing each NMF weight by their sum. Next, these relative contributions were multiplied by the burden of clustered mutations (per Gb of alignable DNA) observed in that sample.
Known SHM mutational signature
The empirical mutational signatures of SHM in human lymphocytes-the S5F model-data was downloaded from the supporting website of Yaari et al. (Yaari et al., 2013) and processed as follows: the pentamer mutabilities (from file ''Mutability.csv'') were multiplied with the relative probabilities of changing the pentamer central nucleotide to each other nucleotide (''Substitution.csv'') to obtain the pentanucleotide mutation spectrum (with 3 * 4^5 = 3072 variables). This spectrum was then collapsed to the standard 96-variable trinucleotide spectrum by summing across all trinucleotides within a pentamer, in a DNA strand-symmetrical manner. Since the SHM mutations occurring at C:G nucleotide pairs are caused by the AID cytosine deaminase, we further focused on the spectrum at A:T pairs, where POLH is known to be the predominant cause of mutations (Delbos et al., 2007) , and compared these 48 SHM contexts to our clustered signatures (Figure 3bc) . Importantly, our definition of clustered mutations that were provided to the NMF discovery algorithm requires that two mutations within a cluster be the same (A > G clusters only with A > G) and we therefore adjusted the relative proportions of A > C versus A > G versus A > T in the known SHM/POLH spectrum accordingly. In particular, we multiplied the weights of each A > C change by 0.273, each A > G by 0.501 and each A > T by 0.226 (the relative frequencies of three mutation types in SHM), thereby obtaining the expected SHM spectrum under the condition of requiring the same mutations within two-mutation clusters (shown in Figure 3 ). Of note, this adjustment affects the overall correlations (of SHM/POLH to other signatures) across all changes at A:T, but it has no effect on the correlation coefficients found separately for A > G or A > C or A > T individually, since the relative proportions of 5 0 or 3 0 contexts are not adjusted in any way.
Somatic hypermutation target regions
With respect to determining mutation enrichment in the immunoglobulin (IG) genes, for the purposes of analyzing pooled tumor samples in Figure 3D , IG regions were defined as spanning the entire IGH, IGL and IGK loci, after removing the non-unique DNA segments according to the very stringent CRG36 alignability criterion (used generally in our work, see above); this yielded 0.74 Mb of DNA. Only for the purpose of analyzing IG locus mutation burden in individual tumor samples ( Figure S7M ), we applied a less stringent criterion for sequence uniqueness (CRG75) thereby increasing the IG locus coverage to 1.38 Mb of genomic DNA and ensuring a higher sensitivity of detecting suspected lymphocyte-infiltrated solid tumors (via enrichment of RC > RN mutations in IG loci, using regression as described below; shown in Figure S7M ). The SHM off-targets were collected from publications that measured AID activity across the genome in mouse B-lymphocytes, mapped to hg19 coordinates using the UCSC liftOver tool and IG loci excluded to arrive to the final definition of AID off-targets; the CRG36 alignability criterion was also applied.
Epigenomic data sources and processing
The epigenomic data that describes local levels of various histone marks and additionally DNase hypersensitivity was downloaded from Roadmap Epigenomics. We used the 'consolidated' Roadmap datasets, which provide a single continuous-valued track (as bigwig file) per histone mark per cell type, and the fold-enrichment (FE) signal data, containing the ratio of observed ChIP-seq/DNase counts relative to expected background counts, as determined and provided by Roadmap. We considered the FE % 1.0 to indicate absence of that particular chromatin mark (or DNase signal), and these genomic regions constituted the 'bin 0' in our regional mutation enrichment analyses (using regression; see below). The remaining genome regions with chromatin mark FE > 1.0 were divided into n equal-frequency bins, meaning that the bins 1,2,. cover an approximately equal amount of genomic DNA (while bin 0 is of different size and typically larger). For instance, when examining H3K36me3 signal for solid tissues (average over 8 cell types; see below), the bin 0 (with FE % 1.0) spans 2665.2 Mb in the genome, and bins 1-5 span 85.7-85.9 Mb each; for DNase hypersensitive sites (DHS), that is 2710.9 Mb for bin 0 and 76.5-77.1 Mb for bins 1-5. The genome alignability mask (CRG36 track; see above) was then further applied to filter out non-unique DNA across all bins. The number of bins (with above-baseline signal) n was set to 5 in the regression analyses that compare two covariates (H3K36me3 versus RepliSeq/DHS/RNA-Seq; Figures 4C and S4F) and to 3 when comparing four covariates (H3K36me3 versus other chromatin marks; Figures 4D and 4E ). In addition, n = 3 bins (with FE > 1.0) were also used when analyzing smaller groups of samples (MSI and SETD2 analyses in Figures 5B and 5C and Figure S3G ) in order to ensure a sufficient number of mutations per bin. For the same reason, the analysis of H3K36me3 enrichment of unclustered mutations for single tumor samples (points in Figures 6D and S6G ) exceptionally uses a single H3K36me3 bin (all regions with FE > 1.0, contrasted to bin 0 with FE % 1.0), while adjusting for three RepliSeq bins (plus bin 0, the latest replicating quarter of the genome; see below).
For the analyses of regional mutation rates in solid tumors using regression, the DHS, H3K36me3 and other chromatin mark FE signal was smoothed over a 50-nt sliding window (arithmetic mean) and then averaged over 8 cell types originating from solid tissues (both tumors and normal cells). The Roadmap codes are: E017 LNG.IMR90 (fetal lung fibroblasts), E114 A549 (lung adenocarcinoma), E117 CRVX.HELAS3.CNCR (HeLa cell line, cervical cancer), E118 LIV.HEPG2.CNCR (HepG2 cell line, liver cancer), E119 BRST.HMEC (mammary epithelial normal cells), E127 SKIN.NHEK (normal human epidermal keratinocytes), E125 BRN.NHA (NH-A astrocytes), E122 VAS.HUVEC (blood vessel endothelium). For chromatin mark analyses concerning lymphocytes ( Figures 4C-4E and S4F, top panels), we used an average over 3 blood cell types in Roadmap: E115 BLD.DND41.CNCR (DND41 T-lymphocyte leukemia; DNase is not available and data from E034 BLD.CD3.PPC is used instead); E116 BLD.GM12878 (B-lymphocyte cell line) and E123 BLD.K562.CNCR (K562 myelogenous leukemia cell line).
Replication timing and RNA-Seq data
Replication timing data was from the ENCODE project, where we used the wavelet-smoothed signal tracks. In particular, for regional mutation rate analysis of the solid tissues, we used an average over 8 ENCODE cell lines (source file names in the form ''wgEncodeUwRepliSeq_____WaveSignalRep1.bigWig'' where the gap contains cell line names: Helas3, Hepg2, Huvec, Nhek, Bj, Imr90, Mcf7, Sknsh). For analysis of blood cells, we used an average over three cell lines (Gm12878, K562 and Gm06990). The signal in these files can range between 0 (latest replicating) and 100 (earliest replicating) and we divided it into n = 4 equal-frequency bins: latest replicating bin 0 to earliest replicating bin 3, all of which therefore span approximately the same fraction of the genome (quartiles). Some analyses use RepliSeq n = 6 bins (bin 0 to bin 5; sextiles), to match the binning scheme for the chromatin marks described above.
The regional RNA-Seq levels were determined as follows: we collected per-transcript mRNA expression from cell types with RNASeq available from Roadmap (file name ''57epigenomes.RPKM.__.gz,'' where the gap is ''nc,'' ''rb'' or ''pc''), marking the genome regions between the transcript start and end as having the RPKM value supplied for that transcript. Additionally we collected RNA-Seq levels of the expressed intergenic contigs provided in ''RNAseq_intergenic.tar.gz.'' We averaged the RPKM over different cell types, while using the same 8-cell type (solid tissue) and 3-cell type (blood) datasets as for Roadmap ChIP-Seq/DHS Roadmap data, except when RNA-Seq data was not available. In particular, in the 8-cell set, we substituted E096 (lung primary tissue) and E071 (brain, hippocampus, primary tissue) for E017 (fetal lung fibroblasts, IMR90) and E125 (brain NH-A astrocytes, primary cell culture), respectively, since the latter two did not have RNA-Seq data. In the 3-cell set, we similarly substituted E038 (BLD.CD4.NPC; CD4 Naive Primary Cells) for the original E115 (DND41 T cell leukemia cell line). With respect to dividing into genome bins, the RNASeq data was treated similarly as the ChIP-Seq data, where the threshold for the (non-expressed) bin 0 was set to = 0.0 RPKM and also included all the intergenic DNA that was not explicitly listed in the expressed intergenic contigs. All remaining regions with > 0.0 RPKM were divided into n = 3 or n = 5 approximately equal-frequency bins, depending on the analysis (same as for ChIP-Seq). For the solid tissue, 8-cell set, bin 0 spanned 1535.4 Mb, while for n = 5, bins 1-5 spanned 272-333 Mb each; for n = 3, bins 1-3 spanned 470-553 Mb each.
Global analyses of mutation densities across chromatin states
For the analysis of mutation enrichment in the 18-state ChromHMM chromatin segmentation scheme ( Figure S3C) , we downloaded the 18-state segmentation for Roadmap cell types and combined them in the following manner: all genome regions that were assigned to a chromatin state in at least two Roadmap cell types that originate from different tissues were marked as globally exhibiting that state. The descriptions of individual states are: TssA (active TSS), TssFlnk (flanking TSS), TssFlnkU (flanking TSS upstream), TssFlnkD (flanking TSS downstream), Tx (strong transcription), EnhG1 (genic enhancer 1), EnhG2 (genic enhancer 2), EnhA1 (active enhancer 1), EnhA2 (active enhancer 2), TxWk (weak transcription), EnhWk (weak enhancer), TssBiv (bivalent/poised TSS), EnhBiv (bivalent enhancer), ZNFRpts (ZNF genes and repeats), Het (heterochromatin), ReprPC (repressed Polycomb), ReprPCWk (weak repressed Polycomb), Quiesc (quiescent).
The principal components analysis (PCA) on regional mutation density of A > G pairs ( Figures 4A, 4B , and S4A-S4E) uses Roadmap data from three cell types (B-lymphocyte GM12878, liver HepG2, and skin NHEK), each considered individually. Here, the clustered A > G mutation density in genome regions with FE > 1.0 (see above) for a particular chromatin mark are considered as features in the input table for PCA, using the following chromatin marks: H3K4me3, H3K9ac, H3K27ac, H3K4me1, H3K9me3, H3K27me3; and in addition to them DNase hypersensitivity. The same PCA additionally includes other features, in particular A > G cluster density in: (i) genes divided into four expression bins (using the gene-level RNA-Seq signal; see above); (ii) segments of gene bodies (divided into fifths along the gene length, considering all RefSeq transcripts excluding the 2.5% shortest and longest transcripts; an additional feature with intergenic DNA was included for comparison); and (iii) six replication timing bins (RepliSeq signal pooled across cell types; explained above). In total, this is 54 features (A > G density in the listed 54 genome regions) used in the PCA. The known SHM on-targets are excluded from all regions in this analysis. Prior to PCA, the features were centered but not scaled to unit variance, meaning that regions with higher variance in mutability have a higher weight in the analysis.
Mutation enrichment testing in genome regions
For determining enrichment of A > G mutation clusters in the analysis in Figures 3 and S3 , encompassing (i) SHM on-and off-targets ( Figure 3D) ; (ii) 18 ChromHMM chromatin states ( Figure S3C) , and (iii) in sliding windows in gene bodies from 5 0 toward 3 0 gene ends ( Figures 3E and S3B) , we used a similar approach as in our previous work (Supek and Lehner, 2015) . In particular, the enrichment was determined as the mutation density (mutation count normalized to the number of nucleotides-at-risk; in this case, all A:T nucleotide pairs) in the region of interest, divided by the baseline mutation density which is (i) for SHM targets, the remainder of the genome; (ii) for each of 18-state ChromHMM analysis, all genome regions that never appear in that particular state across the Roadmap tissue types (see above); and (iii) for the gene body sliding window analysis, the baseline is all intergenic DNA. SHM on-targets are excluded. For both the examined region and the baseline regions, the alignability filter (CRG36 track, see above) was applied to exclude nonunique genome regions. The confidence intervals were found using Woolf's (logit) method, wherein the standard error (SE) for the log odds ratio (log OR) is determined as SE = sqrt(1/a + 1/b + 1/c + 1/d); here, a and b are mutation counts in the region of interest and in the baseline region, and c and d are nt-at-risk in the region of interest and in the baseline; note that c and d are typically large enough to make their contribution to the SE negligible. Then, the 95% CI of the enrichment (OR) is exp(log OR ± 1.96*SE). Prior to calculation of the enrichment (OR) and its 95% CI, we applied the Agresti independence smoothing adjustment for small sample sizes.
Association of mutation signatures to epigenomic data
Histone modifications associated with active chromatin, including H3K36me3, co-occur across the genome. In order to establish independent associations of individual chromatin marks/DNase HS/RNA-Seq/replication timing with regional mutation rates, while accounting for possible confounding effects, we used negative binomial regression (analyses in Figures 4, 5, and 6 ). In particular, we used the glm.nb function from the package MASS (version 7.3.45) in R 3.2.3, with parameters at default values, where the input dataset for the regression was formed as follows: (i) the dependent variable is the mutation counts, pooled over the analyzed set of tumor samples and broken down by the 96 possible contexts/mutation types, see below; (ii) the independent variables are indicators (encoded as unordered factors) of genome bins that reflect an epigenomic variable (or RNA-Seq or replication time), and all possible combinations of these bins are represented in the dataset; (iii) the exposure variable (passed to glm.nb via the offset option) is the log nucleotides-at-risk: the number of base pairs in the human genome (passing the alignability filters, see above) times the number pooled tumor samples, for that particular trinucleotide context and combination of genome bins.
For example (from Figure 4C ), consider the case with 6 genomic bins for H3K36me3 (bin 0 with below-baseline signal i.e., FC < 1, and equal-frequency bins 1-5 with above-baseline signal; see above) and 6 equal-sized genomic bins for RepliSeq (bin 0 is the latestreplicating, while bin 5 is the earliest). This particular setting yields 6*6 = 36 combinations of the two epigenomic variables. Furthermore, each of the 36 is further broken down by 96 nucleotide contexts/mutation types, thereby controlling for possible differences in trinucleotide composition between the tested genome regions (bins of epigenomic data). Thus, the dataset input to glm.nb has 36*96 = 3456 data points in this particular example. The coefficients of the obtained regression model are the log (base e) enrichments of the mutation rate in each bin of the epigenomic variables, in comparison to genomic bin 0 of the same variable. These coefficients are converted to base 2 and the plots thus show log 2 enrichments. The confidence intervals were extracted from the model by the R confint function (which invokes confint.glm from the MASS package). The clustered and the unclustered set of mutations from the same set of tumor samples were treated independently and coefficients determined in separate runs of negative binomial regression. Moreover, different sets of confounded epigenomic features were combined and then tested in separate regression runs, shown as individual sub-panels in Figures 4C-4E, S4F , and S4G. In particular, H3K36me3 is contrasted against (i) RNA-Seq; (ii) DHS; (iii) RepliSeq; (iv) two enhancer marks (H3K27ac and H3K4me1) + DHS; (v) two promoter marks (H3K4me3 and H3K9ac) + DHS; and importantly (vi) two chromatin marks known to be associated to transcribed gene bodies, H3K79me3 and H4K20me1 + RnaSeq expression levels. All p values are by two-tailed Z-test on the regression coefficient, as provided by the R summary function (which invokes summary.glm).
Microsatellite instability and SETD2 tests
The MSI phenotype labels (which imply a failure in the MMR pathway of the corresponding tumor samples) were obtained for the different samples as follows: (i) for the TCGA samples, the clinical data (files labeled ''auxiliary'') provides MSI labels for the three cancer types that also have WGS available: COAD and READ (here jointly called CRAD), UCEC and STAD. We considered the MSS and the MSI-L (low) samples as MSS, and MSI-H samples as MSI; (ii) for the liver cancers in Fujimoto et al. (Fujimoto et al., 2016) , a single tumor sample was labeled as MSI in the publications (with identifier RK308). Since this tumor was originally classified as a biliary phenotype liver cancer, our analysis compared it to other MSS tumors of that same subtype of liver cancer; (iii) for the Wang et al. stomach cancer study we assigned putative MSI labels based on the global indel burden (> 10,000 indels); (iv) for the breast cancers in the BRCA-EU study in the ICGC data portal, we assigned putative MSI labels to tumor samples with > 3,000 indels (PD23564, PD23579, PD24189, PD6412, PD5937, PD24193, PD9604, PD24320 and PD11365).
With respect to the SETD2 analyses ( Figures 5C and S3H) , we considered the TCGA studies with kidney cancer and liver cancer samples where the copy number variants were called. The SETD2 copy-number and mutation data was downloaded from the cBioPortal and matched to our set of WGS. We considered those genomes with a putative homozygous deletion (marked as 'DeepDel' in cBio) or a nonsynonymous mutation in the SETD2 gene as SETD2 mutant and the rest as SETD2 wild-type. The analyses in Figure 5 that compare MSI versus MSS tumors and SETD2 wild-type versus mutant tumors with respect to regional A > G cluster enrichment do not have requirements for the minimum number of 5 clustered mutations at A:T pairs per sample, in order to maximize coverage with (normally low mutation burden) kidney cancers.
Since the FDR distributions of MSI tumors are shifted toward higher values (pooled FDR values for each study/sample set is provided in Figures S3F-S3H) , we tested if the false-discovery fraction of clustered mutations in MSI tumor samples could be responsible for the observed differences. In particular, we added to the MSS set of tumors in each study simulated false-positive A > G clustered mutations. In the pairwise distance histograms (Figure S3F ), they were, conservatively, drawn from a uniform distribution distances up to 500nt. For each study, we added the needed number of simulated false-discovery (FD) clustered mutations such that the MSS group would match the MSI group in terms of FDR. We also added simulated FD clustered mutations in the test for regional (H3K36me3) enrichment via regression ( Figure S3G ); in this case, FD clustered mutations were sampled from the genomic distribution of the unclustered mutations. This assumes, conservatively, that all such FDs would be exclusively A > G changes and not other types of mutations that are not considered in the regression analysis.
Contribution of clustered A > G process to the unclustered mutation burden
The rate of clustered A > G changes for each tumor sample was found by dividing by the number of all mutations at C:G nucleotide pairs. The normalization is based on the assumption that the process generating A > G clusters (markers of the POLH signature) creates a negligible amount of mutations at C:G pairs. This is a conservative assumption since deviations from it would cause the estimated POLH contributions toward the unclustered burden to be biased downward. The same normalization was applied for the rates of unclustered A > G ( Figure 6A ), A > C or A > T changes ( Figure S6C ) and also for these three mutation types broken down by their 5 0 context ( Figure S6D ). In the analyses concerning A > G rates, we excluded one liver cancer sample (RK116, from the LIRI-JP study in ICGC) which had an extremely low burden of unclustered changes at C:G pairs (total only 16 mutations in the entire WGS) and thus exhibited excessive apparent A > N rates after the normalization.
After having determined the rates, we used robust regression (rlm function in the MASS package in R, with maxit = 100 and other parameters at default) where the independent variable x was the square root of the clustered A > G rate, and the dependent variable y were the square roots of the unclustered rates of A > G/A > C/A > T changes (possibly limited to a particular 5 0 context). The coefficients of determination shown on the scatterplots were estimated, conservatively, using the pseudo R 2 WLS method after Willet and Singer.
In order to estimate the contribution of the putatively POLH-driven mutagenesis to the overall mutation burden at A:T pairs in a cancer type, we extracted the y intercept of the regression fit and its 95% C.I. by the R function predict (for x = 0); this would correspond to the (square root of) the unclustered A > N rate in the absence of the process that generates clustered A > G. Then, 1 -intercept 2 / (mean y) 2 is the relative contribution of the clustered A > G process toward the unclustered mutation burden in that set of tumor samples. Substituting the intercept with the lower/higher bounds of its 95% C.I. in this formula yields a confidence interval for the relative contribution to the unclustered burden. Of note, the above estimates do not necessarily imply a direct causation by POLH but may reflect indirect effects of a common upstream mutagenic event. However, parsimony suggests POLH mutagenesis as the likely explanation for mutations at POLHpreferred A:T contexts (Figures 6B and S6D) . Moreover, if the upstream process additionally causes C:G pair mutations, which we used in the normalization to rates, this would further bias our estimates conservatively.
Clinical data and association with mutation signatures
The clinical data on liver cancers (the ICGC studies LINC-JP and LIRI-JP) were collected from the supplementary material (Table S1) of the corresponding publication (Fujimoto et al., 2016) . It was processed in the following manner: the provided ''Liver Fibrosis'' score (following New Inuyama Classification) was rounded down, e.g., ''1$2'' was recorded as ''1.'' The ''vessels/ducts invasion'' label was set to 1 if either of the original features ''Portal vein invasion,'' ''Hepatic vein invasion,'' ''Hepatic artery invasion'' or ''Bile duct invasion'' was > 0. The ''Hepatitis B evidence'' label was set to 1 if serology was HBV or HBV/HCV, and either fibrosis > 1 or HBV reads R 5; the ''Hepatitis C evidence'' label was set to 1 if serology is HCV or HBV/HCV and fibrosis is > 1. ''Alcohol intake'' (levels 0-3) and ''smoking'' (binary) are as in original data; the legends for these labels are from Table S1 in (Fujimoto et al., 2016) . Therein, the four levels of alcohol consumption were labeled as ''no alcohol intake'' (0), ''social drinker'' (1), ''$60g every day'' (2) and ''60g and more every day'' (3). The ''Histological type'' label in the original data can take the values ''HCC'' (hepatocellular carcinoma, the most common subtype), and ''ICC'' or ''cHCC/CC'' for the less common billiary phenotype liver cancers; this analysis examines only HCC. In five HCC tumors, we suspected possible MMR failures based on the mutation burden of indels (top 5 HCC samples have >600 indels per WGS: RK126, RK023, RK190, HX13, and RK119) and we excluded them from further analysis as a precautionary measure. Moreover, tumor samples without corresponding alcohol consumption or smoking data were not included. Our final set of HCC liver cancers from Fujimoto et al. (with clustering FDR of individual samples %20% at %100 nt distance, A:T pairs only) comprises n=240 WGS, with the pooled clustering FDR of 3.2%.
On this hepatocellular carcinoma dataset, we performed two kinds of regression analyses using negative binomial regression (glm.nb function from the R package MASS version 7.3.45). First, we examined the association of the total burden of A > G clusters with the clinical covariates. Here, the count of the clustered A > G mutations is the dependent variable, while the clinical data (all encoded as factors) are the independent variables; there is no explicit exposure variable in this regression. The coefficients of the regression model are the log enrichments (converted to base 2 before plotting) of the clustered A > G burden in a tumor with a certain level of the variable, compared to the baseline level of that variable, and after adjusting for the other covariates. The baseline level for alcohol (0) is labeled ''no alcohol intake'' in the original publication. Second, we examined the relative enrichment of A>G clustered mutations in H3K36me3-rich regions. Here, the dependant variable is the count of A>G clustered mutations in the regions where the H3K36me3 fold-enrichment signal (averaged across 8 Roadmap cell types, see above) is >1.0. Furthermore, an additional exposure variable is added, which is the log count of A>G clustered mutations in the entire alignable genome, irrespective of H3K36me3. The 95% confidence intervals were extracted from the regression model using the confint function (which invokes confint.glm from the MASS package) while the p-values that a coefficient is different from 0 were extracted using the R summary function (which invokes summary.glm and uses a two-tailed Z-test on the regression coefficient to determine significance). Pooled p-values are by the Fisher's method for combining p-values. In both setups described above, the unclustered A>G mutations are processed in a separate regression run, in the same way as the clustered A>G mutations are. The resulting significance levels in the liver cancer tests and in the other studies (see below) were FDR adjusted using the q-value method (R Bioconductor package qvalue, function qvalue with pi0.method=''bootstrap'').
In addition to the hepatocellular carcinoma, we further evaluated an association of alcohol consumption to the clustered A > G burden in three other smaller cohorts of pancreatic adenocarcinoma (PACA-AU in the ICGC, n = 94), esophageal adenocarcinoma (ESAD-UK in the ICGC, n = 87) and head-and-neck squamous cell carcinoma (HNSC in the TCGA, n = 28). In these validation datasets, we required clustering FDR % 40% for individual tumors to increase coverage with tumor samples, which resulted in a pooled clustering FDR = 2.3% for PACA-AU, 25.0% for ESAD-UK, and 11.7% for TCGA HNSC (at A:T nucleotide pairs, for % 100 nt clustering distance). The PACA-AU clinical data was collected from the supplementary material of the corresponding publication, where the ''daily drinker'' and ''weekly drinker'' levels were merged; the baseline level 0 is labeled ''No History of Chronic consumption'' in the original publication. The ESAD-UK clinical data was downloaded from the ICGC data portal (''donor_exposure.all_projects.tsv'' file) where smoking was encoded as: 0, if tobacco_smoking_intensity (henceforth, TSI) = 0 or tobacco_smoking_history_indicator (TSHI) = ''Lifelong non-smoker (< 100 cigarettes smoked in lifetime)''; 1, if TSI > 0 but % 20; 2, if TSI not provided but TSHI states current smoker or reformed smoker; 3, if TSI > 20. Furthermore, alcohol use was encoded as: 0, if alcohol_history_intensity (AHI) = ''None''; 1, if AHI=''Occassional Drinker (< once a month)''; 2, if AHI=''Social Drinker (> once a month, < once a week)''; and 3, if AHI=''Daily Drinker'' or ''Weekly Drinker (>=1x a week)''. Cases where alcohol_history=''Don't know/Not sure'' are ignored. We further tested other ICGC studies with sufficient alcohol annotations (nR17 samples), PRAD-UK, SKCA-BR and CLLE-ES, using the same encoding scheme (where additionally the cases where AHI=''Not Documented'' but alcohol_history=''yes'' are also encoded as 1), but found no association of A>G clusters to alcohol consumption in those studies. Finally, the TCGA HNSC clinical data was encoded with the following alcohol categories: 0, if alcohol_history_documented=FALSE; 1, if alcohol_history_documented=TRUE and alcohol_consumption_frequency%1; 2, if alcohol_consumption_frequency>1 (days per week). Smoking was divided into: 0, lifelong non-smokers; 1, reformed smokers; and 2, current smokers. Finally, we also tested further studies of smoking-caused cancer types in the TCGA: lung cancers (TCGA LUSC and LUAD, n=69, pooled FDR=16.9%) and urinary tract cancers (TCGA BLCA, KIRC, KIRP, and KICH, n=59, pooled FDR=4.5%). Here, we encoded smoking into four levels, determined by the number of pack-years smoked, similarly as for the ESAD-UK data (see above).
With respect to testing association of the burden of various mutational signatures to the smoking history of patients, we compared the Signatures C1-C9 discovered in this work to the previous general (non-clustered) mutational signatures known to be linked to tobacco smoking, Signature 4 and Signature 5 (Alexandrov et al., 2016) , here referred to as S4 and S5. In order to infer the levels of S4 and S5 in our set of tumor samples, we used regression, in particular the R package glmnet, function cv.glmnet with alpha = 0.5 (thus invoking the elastic net regularization) while also requiring all coefficients to be non-negative (lower.limits = 0). For each tumor, the elastic net was used to predict the observed non-clustered mutation spectrum from the 30 previously known mutation spectra (Alexandrov et al., 2013) which also include S4 and S5. Then, the estimated relative contribution of S4 to a tumor is its regression coefficient, divided by the sum of all regression coefficients (of which many will be zero), and similarly so with S5. The number of mutations contributed by S4 or S5 is its relative contribution multiplied by the overall mutation load. The association of mutation burden of each signature with smoking is tested using a Mann-Whitney test (one-tailed, for enrichment in smokers) and FDR adjusted as above ( Figure S7I ). The association of a signature with the number of pack-years smoked divided into three categories: % 10, 10-30, and > 30 ( Figure S7J ) was tested using a randomization test for trend (R package perm, function permTS). The ability of clustered signatures (C5, C6 and C9) and of the non-clustered signatures (S4 and S5) to predict smoking history on out-of-sample data was tested using cross-validation: the confusion matrices in Figures S7K and S7L show out-of-bag prediction accuracy obtained by a Random Forest classifier (R package randomForestSRC, function rfsrc) . The 95% C.I. for the overall accuracy (% patients correctly assigned to one of the 3 classes) are obtained via the R function prop.test (Wilson confidence intervals, with Yates' continuity correction).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical details can be found in the figure legends, or in the Method Details section. Figure S1 . Discovery of Prevalent Trends in Clustered Mutational Signatures across Cancer Genomes, Related to Figure 1 (A and B) The false discovery rates (FDR) for clustering of somatic single nucleotide variants (henceforth, mutations) increase the with overall mutation burden of a tumor sample (x axis) and are moreover higher when allowing larger inter-mutation distances and in mutation-dense, late-replicating regions within genomes. FDRs were estimated by comparing the observed number of clustered mutations versus the expectation from randomizing mutation coordinates within % 500kb, thereby controlling for the megabase-scale mutation rate heterogeneity (STAR Methods). Points are individual genomes, each shown thrice with different FDRs depending on distance thresholds (A) and replication time-based genome regions (B). Curves are loess fits.
(C) Overview of the clustered and unclustered mutation burden in the dataset used for clustered signature discovery. 1159 whole-genome sequences were retained (green bars), while others were discarded based on low numbers of clustered mutations (n < 10, gray bars) or on high false discovery of clusters (FDR > 20%, pink bars;). Ultramutated samples with > 100 SNVs/Mb were discarded prior to any analyses in this work. Tissue types with > 50 samples are individually labeled on x axis. CLL, chronic lymphocytic leukemia. SNV, single nucleotide variant. (D and E) Histograms show the number of tumor samples (D) and the cumulative true positive clustered mutation counts (E) at different FDR thresholds (shading) and stratified by the total mutation burden in tumors (x axis). An inter-mutation distance threshold of 500 bp provides a tradeoff between broader coverage with tumor samples at a given FDR (better at shorter distances; e.g., 200 bp shown) and broader coverage with clustered mutations per tumor sample (better at larger distances; e.g., 1000 bp). In (d), y axis is cut off at 25,000. (F and G) A principal components (PC) analysis on the relative prevalence of clustered mutational spectra across tumor samples outlines three common signatures (see Figure 1B) . Tumors of certain tissues-of-origin are enriched toward higher PC2 values (F) , meaning that the mutation clusters observed in such tumors are often dominated by a R > T clustered signature ( Figure 1B ; panel (G) here), where R is a purine. The FDR adjusted p values are from a Mann-Whitney test on PC2 (F) scores for each tissue versus all others combined. In legend, tissues are ordered by FDR (most confident first). In (G) , Pearson correlation of individual mutational contexts with PCs 1-6 reveals systematic trends also in PC3-6, e.g., clustered C > T changes captured in PC3 or clustered A > C in PC4.
(H) Tumor genome sets from same or similar tissues-of-origin, but collected from different studies, tend to show similar placement in the PC1/PC2 plot. Signatures C1-C9 are similarly or better supported than the known C10 and C11 in this dataset (by SI, panel c), suggesting that the estimate of 9 signatures is conservative.
(F) NMF weights of the 96 unclustered contexts that were discovered alongside the 96 clustered contexts for Signatures C1-C9 (shown in Figure 1E ); y axis in panel f is not to scale with y axis in Figure 1E ; scatterplots in Figure 1D can be used to compare absolute magnitudes of clustered versus unclustered NMF weights in C1-C9).
(G) A comparison of variant allele fractions (VAFs) between pairs of mutations within a cluster (pink) and between clustered and nearby unclustered mutations (teal) provides an independent estimate of clustering false discovery rates.
(H) Signature C3, representing clustered and unclustered APOBEC-signature C > T and C > G changes, is observed at very high levels in bladder and squamoustype tumors (also, exceptionally in rare breast cancers) and predicts overall mutation burden, unlike the APOBEC signatures C1 and C2. 50  100  150  200  250  300  350  400  450  500  50  100  150  200  250  300  350  400  450  500  50  100  150  200  250  300  350  400 (A) Histograms of distances of clustered A > G mutations to the first nearest change at a C:G nucleotide pair, provided separately for various genomic regions (columns of panels; refer to the STAR Methods for definitions). In case a certain mutation falls in more than one of the listed regions, the one leftmost matching column has priority; mutations do not count multiple times. x axis show relative frequency in each bin truncated at 0.5. Empty space in place of a bar means 0 mutations. The proportion of A > G changes where nearest mutation at C:G is > 100 kb away is not explicitly shown on plot but counts toward establishing the proportions, i.e., they add up 1.0 when including also that class of mutations. Sets of tumor samples are as in , comparing counts of A > G mutation pairs at distances of 2-50 nt (dashed vertical line) versus 51-500 nt for different listed cases: a broad set of MSI % 40% FDR versus MSS (top), a lower-coverage set of MSI % 20% versus MSS (middle), and the broad MSI set versus the MSS set to which additional false discovery clusters were introduced via simulation (STAR Methods), in order to obtain an equal pooled FDR as the MSI set. y axis shows relative frequencies, which sum to unity for each distribution. Error bars are Wilson confidence intervals (95%), with Yates' continuity correction. Sample counts (n) show number of tumors with at least one A > G pair within shown distance. Crosses show relative frequencies in bins for repeated subsamples of the MSS group such that the number of tumors n matches that in the MSI group of the same study. (G and H) Enrichment of clustered A > G changes in H3K36me3 marked chromatin is lost in MMR-deficient, MSI tumors (G) and in tumors harboring a mutation or a putative homozygous deletion in the SETD2 gene (H). As in Figures 5B and 5C , plots show coefficients and 95% C.I. (normalized to base 2) from negative binomial regression, where the H3K36me3 enrichment is found to be robust after adjusting for gene expression levels (top row), for open chromatin (estimated via DNase hypersensitivity, middle row) and for replication time (bottom row). Sets of MSS tumors to which simulated false discovery mutation clusters were introduced in order to match the pooled FDR of the MSI tumors (STAR Methods) are shown in the rightmost column in (G) . Simulated subsampled sets (ten iterations) of MSS tumors that match the n MSI tumors are provided in (G) , and similarly when matching the SETD2 mutant and SETD2 wild-type groups by number of tumors in (H). Figure 4cde and in panel (F) . In (F and G) , the log enrichments are the coefficients from negative binomial regression and their 95% C.I., converted to base 2. All enrichments are relative to the lowest genomic bin of each feature (bin 0; see STAR Methods), which would thus have log 2 enrichment = 0 and is not shown on plot. Each sub-panel, and also clustered and unclustered mutations therein, are from a separate regression runs. (A) After adopting stringent criteria for calling mutation clusters (restricting to A:T pairs and requiring % 100 nt inter-mutation distance), an extended set of tumor samples is available due to reduced false discovery. The DNA strand-coordination requirement was retained, and, additionally, since POLH could conceivably create A > G together with the (less frequent) A > T or A > C changes in a single run, such mixed clusters were allowed in this analysis. Shown set of tumor samples and the ordering along x axis is same as in Figure S1C (A-E) The genomic burden of clustered A > G mutations (at % 100nt) is associated with higher alcohol intake levels, after adjusting for other known covariates, in four cancer types that are known to be linked to alcohol consumption: hepatocellular carcinoma (A), pancreatic adenocarcinoma (C), esophagus adenocarcinoma (D), head and neck squamous cell carcinoma (E) . In addition, the relatively large hepatocellular carcinoma dataset (Fujimoto et al., 2016) additionally permitted an analysis of targeting of A > G changes toward H3K36me3-marked chromatin (after adjusting for overall genomic mutation burden; STAR Methods). In addition to daily alcohol consumption, the only other covariate associated with both A > G burden (A) and H3K36me3 targeting (B) was gender. Pooled clustering FDR was 2.3% (for PACA-AU) to 25.0% (for ESAD-UK) datasets. Statistical significance was by Z-test (two-tailed) on the coefficients from negative binomial regression, FDR-adjusted by the q-value method. (F and G) Tobacco smoking is not positively associated with clustered A > G burden in cancer types caused by direct exposure to smoke (lung adenocarcinoma and squamous cell carcinoma; (F) , but it is associated with A > G burden in urinary tract cancers known to be caused by smoking (bladder and kidney cancers; (G) .
(H-J) Broad associations of mutational signatures with tobacco smoking in multiple cancer types, including the known non-clustered Signatures 4 and 5 (S4, S5; top rows) (Alexandrov et al., 2016) and our clustered signatures C5 (R > T changes, middle row), C6 and C9 (bottom rows). The mutational spectra of C5 (and the related C6/C9) are distinct from the known S4 and S5 (H) but all five signatures are robustly increased in ever-smoker (purple) versus never-smoker (gray distributions) patients (I) across multiple known smoking-associated cancer types: kidney, lung adenocarcinoma, cervical, squamous cell cancers (lung,
